---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-011597"
form_type: "8-K"
ticker: "IMNN"
cik: "0000749647"
company_name: "Imunon, Inc."
filed_at: "2025-08-05T23:59:59+00:00"
generated_at: "2026-05-17T21:10:55.692841+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Imunon Q2 net loss narrows to $2.7M, cash $4.7M; first patient dosed in Phase 3 ovarian cancer trial

## Summary
- Net loss $2.7M ($2.15/shr) vs $4.8M ($7.64/shr) YoY; operating expenses down 45% to $2.8M.
- Cash $4.7M at June 30; received $3.1M in July from warrant exercises and ATM; sufficient into Q4 2025.
- First patient dosed July 30 in Phase 3 OVATION 3 trial of IMNN-001 for advanced ovarian cancer; 3 sites open, goal 20 by year-end.
- Declared 15% stock dividend (0.15 shares/share) payable Aug 21, 2025 to holders of record Aug 7.
- Completed 15:1 reverse stock split effective July 25; Nasdaq listing extension granted.

## SEC filing metadata
- accession: 0001493152-25-011597
- form_type: 8-K
- ticker: IMNN
- cik: 0000749647
- company_name: Imunon, Inc.
- filed_at: 2025-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/749647/000149315225011597/0001493152-25-011597-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/749647/000149315225011597/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-011597
- JSON: https://secwatch.observer/filing/0001493152-25-011597.json
- Plain text: https://secwatch.observer/filing/0001493152-25-011597.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.